GleamWall
中文EN

ASND Ascendis Pharma A/S IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1612042 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY98.0%
TTM net income YoY39.7%
TTM EPS YoY42.4%
Revenue 3-yr CAGR141.4%
Net income 3-yr CAGR—

Margins

Gross margin86.8%
Operating margin-18.9%
Net margin-31.7%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-18.4%
ROIC (approx.)-111.1%
Asset turnover0.58x

Leverage & solvency

Liabilities / assets112.5%
Debt / equity—
Current ratio1.04x
Interest coverage-1.69x

Cash quality & payout

Operating cash flow / net income-0.24x
Accruals ratio-22.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR 2025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-31
Income statement
Revenue247.50M213.63M158.04M100.95M173.92M57.83M36.00M95.89M
Cost of revenue23.60M22.35M31.45M17.52M14.02M11.20M11.46M7.57M
Gross profit223.90M191.28M126.60M83.44M159.89M46.63M24.53M88.33M
R&D expense78.15M66.88M71.99M86.60M79.30M73.54M83.48M70.69M
SG&A expense135.85M113.40M107.56M101.05M80.21M69.83M74.31M66.78M
Operating income9.90M11.00M-52.95M-104.21M383,000-96.74M-133.26M-49.15M
Interest expense-64.06M66.90M33.02M44.79M-4.98M25.35M19.62M77.16M
Pretax income-26.70M-57.37M-35.01M-93.56M-37.38M-98.18M-109.15M-128.53M
Income tax6.86M3.62M3.85M1.06M1.08M1.02M229,0002.51M
Net income-33.56M-60.99M-38.85M-94.63M-38.47M-99.20M-109.38M-131.03M
EPS (basic)—-1.00-0.64-1.58—-1.72-1.91-2.30
EPS (diluted)———-1.58—-1.72-1.91-2.30
Weighted avg. shares (diluted)——63.91M———60.80M—
Balance sheet
Cash & equivalents616.04M539.09M494.05M517.92M559.54M625.51M258.70M320.24M
Receivables141.33M134.73M110.45M66.69M166.28M33.10M49.16M41.09M
Inventory301.53M302.02M303.38M293.07M295.61M265.43M251.20M232.68M
Current assets1.11B1.02B952.96M921.49M1.06B973.74M627.32M664.11M
PP&E, netmay include right-of-use assets (IFRS)146.48M101.76M93.54M92.45M98.71M97.52M104.04M107.16M
Total assets1.30B1.15B1.09B1.06B1.18B1.09B758.30M802.50M
Current liabilities1.07B986.48M935.00M885.51M907.86M838.46M847.74M798.97M
Short-term debt429.39M426.24M418.07M449.56M458.21M422.06M432.19M424.98M
Long-term debt385.25M331.37M330.19M357.31M365.08M338.93M219.05M229.63M
Total debt814.64M757.61M748.26M806.87M823.29M760.99M651.24M654.61M
Total liabilities1.47B1.33B1.28B1.25B1.29B1.19B1.08B1.04B
Shareholders' equity-162.82M-174.07M-187.57M-189.81M-105.71M-97.32M-321.13M-238.18M
Net debt198.60M218.52M254.21M288.95M263.74M135.48M392.55M334.37M
Cash flow statement
Operating cash flow73.40M2.15M-7.34M-14.31M-87.18M-56.13M-61.31M-101.58M
Capital expenditure—————467,000342,000199,000
Free cash flow—————-56.60M-61.65M-101.78M
Investing cash flow-3.39M-53,000-4.34M-703,000-384,000-503,000608,0007.16M
Financing cash flow8.52M38.85M6.98M-18.02M87,000427.87M-2.46M18.42M
Stock-based compensation29.95M30.64M30.02M25.56M26.22M25.96M26.05M17.28M
Share buybacks00017.40M00——

Free plan shows the latest 8 periods; Pro shows all 36 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.